TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/12/24 16:30 | 8/9/24 | DSGN | Design Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | William Arsani | CA | D | S | -3,463 | 4.25 | 0 | -815 | -16 | 4,218 | I | |||||||||||||||
9/6/23 17:13 | 3/30/21 | DSGN | Design Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | William Arsani | CA | D | P.a | 14,000 | 20.00 | 0 | 700 | 34 | 2,733 | I | |||||||||||||||
8/30/23 18:02 | 8/28/23 | DSGN | Design Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | William Arsani | CA | D | P.m | 5,374 | 2.40 | 0 | 2,235 | 80 | 5,033 | I | |||||||||||||||
3/22/22 19:28 | 3/21/22 | DSGN | Design Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | William Arsani | CA | D | P | 475 | 18.99 | 0 | 25 | 0 | 6,048 | I | |||||||||||||||
9/2/21 17:06 | 8/31/21 | DSGN | Design Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | William Arsani | CA | D | P | 618 | 15.45 | 0 | 40 | 1 | 6,023 | I | |||||||||||||||
4/1/21 18:12 | 3/30/21 | DSGN | Design Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | William Arsani | CA | D | P.d | 14,000 | 20.00 | 0 | 700 | 13 | 5,983 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |